Price Disclosure (pre - 1 December 2010)

Please note: The information on this page is no longer current and is only included here for historical reference.

Current information is maintained on the Price Disclosure (SPD) page.

 

 

 

 

Price Disclosure Requirements

Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.

Price disclosure requirements under Part VII of the National Health Act 1953 commenced on 1 August 2007. Under those requirements the responsible persons for some multiple-brand medicines are required to provide information to the Department of Health & Ageing, including their revenue for supply of those brands of medicine to wholesalers and approved pharmacists, and the volume of sales. Price disclosure information provided to the Department will be used to determine whether there will be a price reduction. Price reductions that result from price disclosure will apply to every brand that has the same drug with the same manner of administration as those brands for which price disclosure information was provided.

Until 1 January 2011 price disclosure requirements and any associated price reductions apply to pharmaceutical items that have drugs in Part A of F2. Thereafter those requirements and any associated price reductions will apply to pharmaceutical items that have drugs on the consolidated F2 list. 

Further detail about the price disclosure requirements is contained within the following documents:

 

Drugs currently under price disclosure

Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.

This page lists those drugs where a brand of a pharmaceutical item is subject to price disclosure requirements and assists responsible persons to identify the relevant reporting periods and due dates for those drugs.

To identify the reporting period and due dates for a manner of administration of a drug, follow the steps outlined below:
1. Identify the listing date of the first mandatory brand for the drug and manner of administration in Table 1 (note: it is important to consider the manner of administration as a single drug can have more than one set of reporting periods and due dates);
2. Based on the listing month of the first mandatory brand(s), identify the reporting periods in Table 2; and
3. Based on the listing month of the first mandatory brand(s), identify the due dates for price disclosure information in Table 3.

Table 1 below is current for all listings up until 1 November 2010.  Further drugs may be added to the list at any time.

Table 1.
List of drugs where a brand of a pharmaceutical item is subject to price disclosure requirements under Part VII of the National Health Act 1953.
Drug Manner of Administration Listing Date of First Mandatory Brand(s)
Alendronic acid Oral 1 Dec 2007
Alendronic acid with colecalciferol Oral 1 July 2009
Amisulpride Oral 1 Aug 2007
Azithromycin Oral 1 Aug 2009
Bicalutamide Oral 1 Aug 2008
Bisoprolol Oral 1 Aug 2009
Cabergoline Oral 1 Aug 2009
Carvedilol Oral 1 Apr 2008
Cefalotin Injection 1 Aug 2008
Ceftriaxone Injection 1 Nov 2007
Cisplatin Injection 1 Oct 2008
Clopidogrel Oral 1 Apr 2010
Doxorubicin Injection/Intravesical 1 Aug 2007
Enalapril with hydrochlorothiazide Oral 1 Apr 2008
Escitalopram Oral 1 June 2009
Famciclovir Oral 1 June 2010
Fluconazole Oral 1 Oct 2007
Fluconazole Injection 1 Dec 2007
Fludarabine Injection 1 Dec 2008
Fosinopril with hydrochlorothiazide Oral 1 Aug 2007
Gemcitabine Injection 1 Apr 2009
Glucose Injection 1 Aug 2009
Irinotecan Injection 1 Apr 2008
Levetiracetam Oral 1 June 2010
Levodopa with Carbidopa Oral 1 Sept 2010
Meloxicam Oral 1 Aug 2007
Memantine Oral 1 Apr 2010
Mitozantrone Injection 1 Aug 2007
Morphine Oral 1 Aug 2009
Naltrexone Oral 1 Dec 2007
Octreotide Injection 1 Dec 2007
Ondansetron Injection 1 Aug 2007
Ondansetron Oral 1 May 2009
Oxaliplatin Injection 1 July 2009
Oxazepam Oral 1 Aug 2010
Oxybutynin Oral 1 Aug 2007
Paclitaxel Injection 1 Jan 2009
Perindopril with indapamide Oral 1 Aug 2007
Prochlorperazine Oral 1 Aug 2010
Risperidone Oral 1 Dec 2008
Sodium Chloride Injection 1 Aug 2009
Sodium Lactate Compound Injection 1 Aug 2009
Sumatriptan Oral 1 Feb 2008
Topiramate Oral 1 Oct 2009
Valproic acid Oral 1 Aug 2007
Vancomycin Injection 1 Dec 2007
Vinorelbine Injection 1 Mar 2009

 

Table 2. Price disclosure reporting periods#
Listing Month of First Mandatory Brand(s) 1st Quarterly Reporting Period 2nd Quarterly Reporting Period 3rd Quarterly Reporting Period 4th Quarterly Reporting Period Incentive Reporting Period
1 January
1 February
1 March
1 April
1 May – 31 July 1 August – 31 October 1 November – 31 January 1 February – 30 April 1 May – 30 April
1 May
1 June
1 July
1 August
1 September – 30 November 1 December – 29 February 1 March – 31 May 1 June – 31 August 1 September – 31 August
1 September
1 October
1 November
1 December
1 January – 31 March 1 April – 30 June 1 July – 30 September 1 October – 31 December 1 January – 31 December

#Responsible persons must begin collecting monthly data from the date of listing for mandatory brands and from the beginning of the month following the election to volunteer to disclose for voluntary brands. The responsible person may be required to collect and submit more or less than three months of data for the initial period of reporting. Thereafter the responsible person is required to collect and submit three months of data each quarterly reporting period. Further information is contained within the National Health (Pharmaceutical Benefits) Regulations and in the PBS Price Disclosure Procedural and Operational Guidelines.

If you are unsure about the reporting periods and due dates for a manner of administration of a drug, or the information you should provide for a particular brand please contact the Department by sending an email to pricedisclosure@health.gov.au or by calling (02) 6289 7335.

  

Table 3: Due dates for the provision of information in accordance with the price disclosure requirements under Part VII of the National Health Act 1953.
table showing Due dates for the provision of information in accordance with the price disclosure requirements under Part VII of the National Health Act 1953
Listing Month of First Mandatory Brand(s) 1st Quarterly Reporting Period 2nd Quarterly Reporting Period 3rd Quarterly Reporting Period 4th Quarterly Reporting Period and Incentive Reporting Period
1 August 1 February each year 1 May each year 1 August each year 1 November each year
1 September 1 June each year 1 September each year 1 December each year 1 March each year
1 October 1 June each year 1 September each year 1 December each year 1 March each year
1 November 1 June each year 1 September each year 1 December each year 1 March each year
1 December 1 June each year 1 September each year 1 December each year 1 March each year
1 January 1 October each year 1 January each year 1 April each year 1 July each year
1 February 1 October each year 1 January each year 1 April each year 1 July each year
1 March 1 October each year 1 January each year 1 April each year 1 July each year
1 April 1 October each year 1 January each year 1 April each year 1 July each year
1 May 1 February each year 1 May each year 1 August each year 1 November each year
1 June 1 February each year 1 May each year 1 August each year 1 November each year
1 July 1 February each year 1 May each year 1 August each year 1 November each year

 

If you are unsure about the reporting periods and due dates for a manner of administration of a drug, or the information you should provide for a particular brand please contact the Department by sending an email to pricedisclosure@health.gov.au or by calling (02) 6289 7335.

For a list of Items Exempt from Price Disclosure Requirements, click on this link.

 

How to send in your price disclosure submission

Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.

For CD/DVD submissions

  1. Complete the appropriate forms and templates that are available on this site.
  2. Save the data in the selected format, and burn to a CD/DVD.
  3. Label the CD/DVD so the Department can easily match it to your Declaration form.
  4. Send the data and Price Disclosure Declaration form to the address below.

For paper based submissions

  1. Complete the appropriate forms and templates that are available on this site.
  2. Send the data and Price Disclosure Declaration form to the address below.

Send to:

Price Disclosure Team

High Cost Drugs/Price Disclosure

Pharmaceutical Evaluation Branch

MDP 952

Department of Health

GPO Box 9848, Canberra ACT 2601

The Department recommends that you use Registered Post.

Enquiries

For enquiries please contact:
Tel: +61 2 6289 7335

Email: pricedisclosure@health.gov.au

 

Submission templates, examples and forms for price disclosure

Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.

Below are the forms and templates you will need to submit information for Price Disclosure.

For CD/DVD submissions

Documents you will need to complete and submit:

Price Disclosure Submission Declaration (PDF 157 KB)

Data to be provided on the following template:

Price Disclosure Template (Excel 27 KB)

Sample template:

Price Disclosure Sample (Excel 28 KB)

For paper based submissions

Complete and submit:

Price Disclosure Submission Form (PDF 155 KB)

Data dictionary

The data dictionary is a detailed description of the data fields in the templates you are filling in.

Data Dictionary (Word 64 KB)

Data Dictionary (PDF 74 KB)